Psoriatic Arthritis News and Research

RSS
Like rheumatoid arthritis (RA), psoriatic arthritis is a chronic inflammatory disease of the joints and connective tissue. The disease causes joint pain and swelling that can lead to crippling along with inflamed and irritated scaly red patches of skin throughout the body. It is a progressive and debilitating disease and because there are no treatments specifically approved for psoriatic arthritis, doctors often use therapies approved for RA, including nonsteroidal anti-inflammatory drugs (NSAIDs) and disease modifying anti-rheumatic drugs (DMARDs). However, no DMARDs are currently approved for use in psoriatic arthritis. There are approximately 300,000 patients with psoriatic arthritis in the United States and the disease affects both men and women most commonly between the ages 30 and 50. Psoriatic arthritis patients are generally treated by rheumatologists and dermatologists.
Early-career physicians receive National Psoriasis Foundation fellowship to study psoriasis

Early-career physicians receive National Psoriasis Foundation fellowship to study psoriasis

Thirteen scientists receive grant to identify new treatments, cure for psoriasis

Thirteen scientists receive grant to identify new treatments, cure for psoriasis

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

Johnson & Johnson sales increase 9.1% to $19.5 billion in second quarter 2014

National Psoriasis Foundation to double the number of researchers studying psoriasis

National Psoriasis Foundation to double the number of researchers studying psoriasis

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

One-third of PsA patients not receiving adalimumab doses to achieve optimal clinical benefit

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Researchers find standard heart disease risk assessment tools for rheumatoid arthritis patients

Researchers find standard heart disease risk assessment tools for rheumatoid arthritis patients

AbbVie's ALIGN study underscores patients’ attitudes and adherence toward TNF inhibitors

AbbVie's ALIGN study underscores patients’ attitudes and adherence toward TNF inhibitors

WHO member states recognize psoriasis as chronic, non-communicable disease

WHO member states recognize psoriasis as chronic, non-communicable disease

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

UCB announces results from PRECiSE clinical trial of Cimzia in patients with Crohn's disease

Covagen begins COVA322 Phase Ib/IIa study to treat patients with rheumatoid and psoriatic arthritis

Covagen begins COVA322 Phase Ib/IIa study to treat patients with rheumatoid and psoriatic arthritis

NPF researchers to get access to Corrona’s psoriatic arthritis registry to improve patient outcomes

NPF researchers to get access to Corrona’s psoriatic arthritis registry to improve patient outcomes

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

New initiative aims to develop Global Psoriasis Atlas

New initiative aims to develop Global Psoriasis Atlas

Leading experts discuss the economic burden of psoriasis and psoriatic arthritis on patient and society

Leading experts discuss the economic burden of psoriasis and psoriatic arthritis on patient and society

With three weeks to go, Obama administration pulls out all the stops in sign up efforts

With three weeks to go, Obama administration pulls out all the stops in sign up efforts

UK waiting times for RA and PsA patients: an interview with Dr Marwan Bukhari, Consultant Rheumatologist at the University Hospitals of Morecambe Bay NHS Foundation Trust

UK waiting times for RA and PsA patients: an interview with Dr Marwan Bukhari, Consultant Rheumatologist at the University Hospitals of Morecambe Bay NHS Foundation Trust